Hence, DC-NeoAg peptide and DC-MAA peptide vaccines prompted the development of detectable anti-PVEC TIL responses, and DC-TBVA peptide vaccines promoted significant levels of CD8+IFN-γ+ TILs reactive against B16 tumor cells, with no vaccines observed to promote T cells reactive against EL4 tumor cells. The gene discussed is CD8A; the disease is neoplasm.